Guangdong Xinbao Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") is a national high-tech enterprise focusing on the research, development, production and sales of traditional Chinese medicine drugs.

The company implements the value of "benevolent and honest, to make benevolent medicine, to be kind and embrace talents, and to value confidence and develop together", adheres to the business philosophy of "honest and trustworthy, win-win cooperation", and is based on the treatment fields such as cardiovascular, respiratory, and digestive. , with pharmaceutical manufacturing as its core business, adhere to the development path of dual-wheel drive of R&D innovation and marketing innovation, gradually form a sustainable development business system with Chinese patent medicine as its business basis, leading the innovation of big health products, and is determined to achieve "building a century-old heart treasure" , benefit the people of the world”.

The company has 5 subsidiaries, covering pharmaceutical, trade, technology research and development, big health, commercial services and other sectors. In 2019, the company invested in the construction of the second and third phases of industry, academia and research bases to build a two-way consortium cooperation model that integrates talent training, scientific research and development, and technological achievements transformation cooperation. Relying on the core regional advantages of the Guangdong-Hong Kong-Macao Greater Bay Area, The company strives to build a "four new" big health industry and research highland with innovative technologies, innovative industries, innovative business formats and innovative models.

The company adheres to the development concept of "science and technology research and development is the primary productive force", strives to build an innovative scientific research platform, and actively carries out industry-university-research cooperation with various universities and research institutes. In 2017, the company was approved to establish the "Guangdong Province Xinbao Mingyou Chinese Patent Medicine Engineering Technology Research Center" and presided over the provincial project "Second Development Research of Famous High-quality Chinese Patent Medicine Xinbao Pills". The company cooperates with the Guangdong Provincial Drug Inspection Institute to carry out the research project on the formulation and revision of drug standards of the National Pharmacopeia Commission "Improving the Quality Standards of Xinbao Pills".

The company produces multiple dosage form products such as pills, tablets, capsules, granules; among them, Xingchen brand "Xinbao Pills" have been sold well in the market for more than 30 years. Its prescription is special, its efficacy is accurate, and it is safe to take. In 2015, the Xingchen Brand Guilu Shen Budding Tablets, which the company has devoted itself to, became a chain terminal supplement incremental product. At the same time, the Pudilan anti-inflammatory series products produced by the company have been favored by partners and consumers with their excellent product quality and good efficacy, and have become a well-known brand of "Traditional Medicine Antibiotics".

The company implements the business strategy of "full products, all terminals, and all channels", builds a chronic disease product system based on the core theory of "heart and kidney treatment", deepens its efforts in the terminal pharmaceutical market, increases county-level terminal coverage, and innovates professional academic promotion system , empower the marketing system with the help of digital channels and intelligent marketing platforms.

Guangdong Xinbao Pharmaceutical Technology Co., Ltd. will always be committed to the cause of human health, strive to provide patients with high-quality health products, provide employees with a career development platform, provide partners with win-win opportunities for collaboration, work together and witness the wonderful future!